333MO - Treatment patterns in patients with mantle cell lymphoma: Updated report of the Asia-Pacific multinational retrospective registry study

Background

To better define the clinical characteristics, treatment patterns, and survival outcomes of patients with mantel cell lymphoma (MCL), we conducted a multinational retrospective registry study for newly diagnosed patients with MCL.

Methods

Data were collected from newly diagnosed MCL patients between January 2008 and September 2019 from 27 hospitals in Asian countries, including China, Malaysia, Japan, Singapore, South Korea, Taiwan, and Thailand. The first interim analysis with 191 patients was previously reported. An updated analysis of 289 patients was performed.

Results

The median age was 64 years (range, 26–90). The most frequently administered 1^st -line regimen was R-CHOP or R-CHOP-like regimens (n = 146), followed by cytarabine-containing regimens (n = 78) including R-Hyper-CVAD (n = 56). The overall response rate (ORR) and the complete response (CR) rate among these patients were 94.7% and 59.0%, respectively. Median progression-free survival (PFS) was 47.6 months, and median overall survival (OS) was 75.7 months. There were no significant differences in PFS and OS between the ASCT (n = 103) and non-ASCT (n = 35) groups among transplant-eligible patients (n=138), with a 5-year PFS rate of 48.6 vs. 32.5% (P = 0.29) and 5-year OS rate of 73.7 vs. 73.7% (P = 0.13), respectively.

Conclusions

Our study demonstrated that the majority of MCL patients in the Asia-Pacific region were treated with rituximab-based regimens in the contemporary era. Compared to previous studies, our real-world analysis showed improved survival outcomes. However, the rate of upfront ASCT was relatively low, and there was no significant difference in survival outcomes according to upfront ASCT.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The work was funded by a research grant from Janssen Pharmaceuticals Ltd.

Disclosure

All authors have declared no conflicts of interest.